Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue (2017 - 2025)

Crinetics Pharmaceuticals has reported Non-Current Deffered Revenue over the past 9 years, most recently at $3.8 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $3.8 million for Q4 2025, down 19.01% from a year ago — trailing twelve months through Dec 2025 was $3.8 million (down 19.01% YoY), and the annual figure for FY2025 was $3.8 million, down 19.01%.
  • Non-Current Deffered Revenue for Q4 2025 was $3.8 million at Crinetics Pharmaceuticals, down from $4.1 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for CRNX hit a ceiling of $7.2 million in Q1 2022 and a floor of $2000.0 in Q4 2021.
  • Median Non-Current Deffered Revenue over the past 5 years was $4.7 million (2024), compared with a mean of $4.1 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: crashed 91.3% in 2021 and later surged 304950.0% in 2022.
  • Crinetics Pharmaceuticals' Non-Current Deffered Revenue stood at $2000.0 in 2021, then surged by 304950.0% to $6.1 million in 2022, then dropped by 22.14% to $4.8 million in 2023, then fell by 0.97% to $4.7 million in 2024, then dropped by 19.01% to $3.8 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $3.8 million (Q4 2025), $4.1 million (Q3 2025), and $4.0 million (Q2 2025) per Business Quant data.